AOD-9604
A modified fragment of human growth hormone comprising amino acids 176-191 with an additional tyrosine residue at the N-terminus. Designed to isolate the lipolytic (fat-burning) activity of growth hormone without its growth-promoting, IGF-1-raising, or diabetogenic effects. Originally developed at Monash University, though it failed to demonstrate significant weight loss in Phase II/III clinical trials.
Typical Dosage
Research: 300 mcg subcutaneous once daily in the abdominal area, on an empty stomach. Often cycled 12 weeks on, 4 weeks off.
Administration
Subcutaneous injection or oral
Mechanism of Action
AOD-9604 is a modified fragment of human growth hormone comprising amino acids 176-191 with an additional tyrosine residue at the N-terminus. This specific region of the GH molecule contains the lipolytic (fat-burning) domain while lacking the receptor binding regions responsible for growth-promoting and diabetogenic effects. The result is a peptide that mimics the fat metabolism effects of growth hormone without stimulating IGF-1 production, bone growth, or insulin resistance.
The primary mechanism involves stimulation of beta-3 adrenergic receptors on adipocytes, which activates hormone-sensitive lipase (HSL) through a cAMP-dependent pathway. HSL catalyzes the hydrolysis of stored triglycerides into free fatty acids and glycerol, which are then released into the bloodstream for oxidation by muscle and liver tissue. Simultaneously, AOD-9604 appears to inhibit lipogenesis — the synthesis of new fatty acids from non-lipid precursors — by downregulating acetyl-CoA carboxylase and fatty acid synthase activity in adipocytes.
Unlike full-length growth hormone, AOD-9604 does not bind to the GH receptor or stimulate JAK2/STAT5 signaling, which is why it avoids the IGF-1 elevation, water retention, and insulin resistance associated with exogenous GH use. However, it should be noted that AOD-9604 failed to show significant weight loss compared to placebo in Phase II/III clinical trials, raising questions about whether its in vitro lipolytic activity translates to meaningful clinical effects at the doses tested.
Regulatory Status
Not FDA approved. Failed Phase II/III trials. GRAS status as a food supplement ingredient. Available through compounding pharmacies.
Risks & Safety
Common: injection site irritation, headache, mild fatigue. Serious: chest tightness (reported in trials), unknown long-term effects due to limited clinical data. Rare: hypersensitivity reactions. Failed Phase II/III obesity trials, raising questions about clinical efficacy. Not FDA approved.
Research Papers
1Published: December 31, 2025
Abstract
Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine. By acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, peptides exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF-1 signaling and satellite cell repair. Recovery-enhancing agents such as epithalon, delta sleep-inducing peptide, and pinealon target circadian and mitochondrial regulators, and neuroactive peptides like selank, semax, and dihexa enhance brain-derived neurotrophic factor and HGF/c-Met pathways critical to neuroplasticity. Although preclinical studies are promising, there is a current lack of clinical trials. This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.
Related Peptides
5-Amino-1MQ
A small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme significantly overexpressed in white adipose tissue of obese individuals. Not technically a peptide but commonly sold alongside peptides in weight management protocols. Works by preserving cellular NAD+ and SAM pools, shifting fat cells from a storage to a fat-burning metabolic state.
Adipotide
An experimental peptidomimetic that destroys blood vessels specifically feeding white adipose tissue, causing fat cell death through ischemia. Developed at MD Anderson Cancer Center using vascular-targeting technology originally designed for anti-cancer applications. Produced significant fat mass reduction in primate studies but development has been severely limited by kidney toxicity.
Cagrilintide
A long-acting analogue of amylin, a satiety hormone naturally co-secreted with insulin from pancreatic beta cells. Developed by Novo Nordisk primarily as the amylin component of the CagriSema combination therapy. Targets a distinct appetite-suppression pathway from GLP-1 agonists, acting on brainstem amylin receptors to reduce meal size and food intake.
CagriSema
A fixed-dose combination of cagrilintide (amylin analogue) and semaglutide (GLP-1 agonist) in a single weekly injection. Targets two complementary appetite-suppression pathways — amylin receptors in the brainstem and GLP-1 receptors in the hypothalamus. Achieved approximately 25% body weight loss in Phase 3 trials, among the highest for any pharmaceutical intervention.